Glenmede Trust CO Na Supernus Pharmaceuticals, Inc. Transaction History

Glenmede Trust CO Na

$20.6 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $39,226 - $47,199	1,123 Added 7.1%	16,946 $613,000
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $2,456 - $2,992	79 Added 0.5%	15,823 $564,000
Q3 2022 Nov 16, 2022	SELL	$28.79 - $35.41 $1,813 - $2,230	-63 Reduced 0.4%	15,744 $532,000
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $6.95 Million - $9.4 Million	-274,410 Reduced 94.55%	15,807 $456,000
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $7.6 Million - $8.77 Million	-266,712 Reduced 47.89%	290,217 $9.38 Million
Q4 2021 Feb 15, 2022	SELL	$26.37 - $34.22 $177,892 - $230,848	-6,746 Reduced 1.2%	556,929 $16.2 Million
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $100,139 - $133,533	-4,254 Reduced 0.75%	563,675 $15 Million
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $40,935 - $50,847	-1,532 Reduced 0.27%	567,929 $17.5 Million
Q1 2021 May 18, 2021	BUY	$24.15 - $31.45 $1.88 Million - $2.44 Million	77,727 Added 15.81%	569,461 $14.9 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $685,450 - $999,518	-38,726 Reduced 7.3%	491,734 $12.4 Million
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $1.65 Million - $2.04 Million	-81,504 Reduced 13.32%	530,460 $11.1 Million
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $2.91 Million - $4.23 Million	-170,115 Reduced 21.75%	611,964 $14.5 Million
Q4 2019 Feb 12, 2020	SELL	$19.93 - $29.13 $2.05 Million - $2.99 Million	-102,635 Reduced 11.6%	782,079 $18.5 Million
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $4.15 Million - $5.44 Million	-162,995 Reduced 15.56%	884,714 $24.3 Million
Q2 2019 Aug 13, 2019	SELL	$29.96 - $38.87 $7.11 Million - $9.23 Million	-237,373 Reduced 18.47%	1,047,709 $34.7 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $2.64 Million - $3.38 Million	80,417 Added 6.68%	1,285,082 $45 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $6.51 Million - $10.5 Million	211,182 Added 21.26%	1,204,665 $40 Million
Q3 2018 Nov 15, 2018	BUY	$42.7 - $56.55 $14.5 Million - $19.3 Million	340,677 Added 52.19%	993,483 $50 Million
Q2 2018 Aug 15, 2018	BUY	$44.1 - $59.85 $882,529 - $1.2 Million	20,012 Added 3.16%	652,806 $39.1 Million
Q4 2017 Feb 15, 2018	SELL	$36.4 - $42.6 $3.21 Million - $3.76 Million	-88,303 Reduced 12.25%	632,794 $25.2 Million
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $26.5 Million - $35.8 Million	721,097	721,097 $0

Others Institutions Holding SUPN

# of Institutions

286

Shares Held

60.7M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$416 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$245 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$204 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$115 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$105 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.14B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

News

Stay updated on Glenmede Trust CO Na with notifications on news.

Account